Yvonne Y Li
机构: Dana Farber Cancer Institute
每年引用次数
引用次数
引用: 8,017
H-指数: 40
I10-指数 : 60
出版物: 124
P33.04 Programmed Death-Ligand 1 (PD-L1) Changes in Non-Small-Cell Lung Cancer (NSCLC): Clinical, Pathologic, and Genomic Correlates
A. Cherniack , L. Sholl , B. Ricciuti , M. Awad
Journal of Thoracic Oncology 16 ( 3)
2021
Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer.
G. Lamberti , L.F. Spurr , Y. Li , B. Ricciuti
Annals of Oncology 31 ( 6) 807 -814
57
2020
Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study.
B.S. Sheffield , B. Tessier-Cloutier , H. Li-Chang , Y. Shen
Current Oncology 23 ( 6) 571 -575
6
2016
Selective targeting of indel-inferred differences in spatial structures of homologous proteins.
YVONNE Y. LI , STEVEN J. M. JONES , ARTEM CHERKASOV
Journal of Bioinformatics and Computational Biology 4 ( 2) 403 -414
2
2006
Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts).
Nicole Grace Chau , Yvonne Y Li , Yin P Hung , Peter S Hammerman
Journal of Clinical Oncology 34 6052 -6052
1
2016
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors
Steven JM Jones , Janessa Laskin , Yvonne Y Li , Obi L Griffith
Genome Biology 11 ( 8) 1 -12
152
2010
Drug repositioning for personalized medicine.
Yvonne Y Li , Steven JM Jones
Genome Medicine 4 ( 3) 27 -27
273
2012
Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations.
Yvonne Y Li , Grace TY Chung , Vivian WY Lui , Ka-Fai To
Nature Communications 8 ( 1) 14121
121
2017
Genomic analysis of a rare human tumor
Steven JM Jones , Janessa Laskin , Yvonne Y Li , Obi L Griffith
BMC Bioinformatics 11 ( 4) 1 -1
8
2010
Near haploidization is a genomic hallmark which defines a molecular subgroup of giant cell glioblastoma.
Tiffany G Baker , Jay Alden , Adrian M Dubuc , Cynthia T Welsh
Neuro-oncology advances 2 ( 1) 155
2020
Improving the specificity of high-throughput ortholog prediction
Debra L Fulton , Yvonne Y Li , Matthew R Laird , Benjamin GS Horsman
BMC Bioinformatics 7 ( 1) 270 -270
93
2006
Diminished efficacy of programmed death-(ligand) 1 inhibition in STK11-and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status
Biagio Ricciuti , Kathryn C Arbour , Jessica J Lin , Amir Vajdi
Journal of Thoracic Oncology 17 ( 3) 399 -410
78
2022
Personalized oncogenomics
Steven JM Jones , Janessa Laskin , Yvonne Y Li , Obi L Griffith
Genome Biology 11 ( 1 Supplement)
2010
Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer
Srivatsan Raghavan , Peter S Winter , Andrew W Navia , Hannah L Williams
Cell 184 ( 25) 6119 -6137. e26
260
2021
Quantification of aneuploidy in targeted sequencing data using ASCETS
Liam F Spurr , Mehdi Touat , Alison M Taylor , Adrian M Dubuc
Bioinformatics 37 ( 16) 2461 -2463
27
2021
Oncogenic drivers and therapeutic vulnerabilities in KRAS wild-type pancreatic cancer
Harshabad Singh , Rachel B Keller , Kevin S Kapner , Julien Dilly
Clinical Cancer Research 29 ( 22) 4627 -4643
14
2023
Impact of aneuploidy and chromosome 9p loss on tumor immune microenvironment and immune checkpoint inhibitor efficacy in NSCLC
Joao V Alessi , Xinan Wang , Arielle Elkrief , Biagio Ricciuti
Journal of Thoracic Oncology 18 ( 11) 1524 -1537
5
2023
Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants
Tikvah K Hayes , Elisa Aquilanti , Nicole S Persky , Xiaoping Yang
nature communications 15 ( 1) 2742 -2742
2
2024
Loss of heterozygosity does not occur in BRCA1/2 mutant pediatric solid and central nervous system tumors
Andrew Groves , Abigail Ward , Yvonne Y Li , Lorena Lazo de la Vega
Pediatric blood & cancer 70 ( 11) e30643 -e30643
2
2023
Abstract HER2-05: HER2-05 Comprehensive genomic characterization of HER2-low breast cancer
Paolo Tarantino , Hersh V Gupta , Melissa E Hughes , Janet L Files
Cancer Research 83 ( 5_Supplement) HER2 -HER2
2
2023